A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia

Grants

Funding Acknowledgements

Trial supported by BeiGene. C Tam has received consulting fees and research support from BeiGene and Janssen. V LeBlond has received consulting fees from Abbvie, Roche and Janssen, has participated on Speakers' Bureaus for Abbvie, Janssen, Roche, and Gilead and has had travel expenses paid for by Roche and Abbvie. R Owen has received honoraria from Janssen, Celgene, and Takeda; consultancy fees from Pharmacyclics, Janssen, and Celgene; and meeting/travel support from Janssen and Celgene. A Tedeschi has served on advisory boards for Janssen, Abbvie and Amgen. W Novotny, S Atwal, A Cohen and J Huang are employees of Beigene and hold stock options. C Buske has received research grants from Janssen and Roche and has participated on advisory boards for Roche, Janssen, Celgene, Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Medical writing and editorial assistance was funded by BeiGene and was provided, under the direction of the authors, by JV Stelten of Bio Connections.